Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis.

Recent clinical trials have established B cell depletion by the anti-CD20 chimeric antibody Rituximab as a beneficial therapy for patients with relapsing-remitting multiple sclerosis (MS). The impact of Rituximab on T cell responses remains largely unexplored. In the experimental autoimmune encephal...

Full description

Bibliographic Details
Main Authors: Nancy L Monson, Petra Cravens, Rehana Hussain, Christopher T Harp, Matthew Cummings, Maria de Pilar Martin, Li-Hong Ben, Julie Do, Jeri-Anne Lyons, Amy Lovette-Racke, Anne H Cross, Michael K Racke, Olaf Stüve, Mark Shlomchik, Todd N Eagar
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-02-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21359213/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/21359213/?tool=EBI

Similar Items